THE
Diabetes
DAILYNEWS© CONCEPTUAL INDEX
"Guava
fruit may benefit type 2 diabetics....."; "Long-Acting
GLP-I agonist Exendin-4 Stimulates Both beta-Cell
Replication and Neogenesis, Resulting in Increased
beta-Cell Mass and Improved Glucose Tolerance in Diabetic
Rats....." "NDC
recommends metformin as first line MONOTHERAPY therapy in
the OBESE (BMI>30) type 2 patient, but also recommends
CAUTION when combining metformin with sulfonylurea
agents......."; "ISRAELI STUDY SHOWS
INCREASED MORTALITY WITH METFORMIN- SULFONYLUREA
COMBINATION THERAPY.........."; "Bristol-Myers
Squibb warned about Glucophage adverse event
reporting............."; "FDA
foolishly rejects important new
antibiotic................"; "Actos
(pioglitazone) approval in Type 2s as monotherapy or in
combination with metformin, insulin, or SFU's cautioned
by edema, weight gain, and anemia but heartened by
lowering triglycerides................."; "Avandia
(Rosiglitazone) approval by FDA cautioned by LDL
increase, edema, anemia, and
weight-gain............."; "The
allele frequency of the PPAR gamma 2 missense mutation
Pro12Ala variant is 0.12 in Caucasian Americans, 0.10 in
Mexican Americans, 0.08 in Samoans, 0.03 in African
Americans, 0.02 in Nauruans............; "D-chiro-inositol
effective in reducing insulin
resistance................"; "Beta Cell
Failure Gets Almost All Type 2 Diabetics In
Time............."; "Type 2
diabetics will eventually require insulin for good
control.........";
|